Guardant Health Inc. (GH)
NASDAQ: GH
· Real-Time Price · USD
57.70
-1.74 (-2.93%)
At close: Sep 10, 2025, 11:49 AM
Guardant Health Revenue Breakdown
| Period Ending | Jun 30, 2025 | Mar 31, 2025 |
|---|---|---|
| Biopharma & Data Revenue | 56.02M | 45.38M |
| Biopharma & Data Revenue Growth | +23.46% | n/a |
| Licensing & Other Revenue | 2.57M | 1.86M |
| Licensing & Other Revenue Growth | +38.19% | n/a |
| Oncology Revenue | 158.69M | 150.56M |
| Oncology Revenue Growth | +5.40% | n/a |
| Screening Revenue | 14.81M | 5.68M |
| Screening Revenue Growth | +160.95% | n/a |
Revenue by Geography
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Us Revenue | 15.4M | 9.86M | 10.22M | 11.37M | 9.12M | 11.14M | 12.44M | 7.29M | 7.89M | 9.8M | 9.08M | 6.31M | 8.31M | 5.23M | 6.14M | 4.36M | 4.23M | 6.37M | 5.31M | 8.96M | 4.91M | 2.9M | 3.5M | 6.17M | 4.98M | 5.41M | 9.11M | 3.76M |
| Non-Us Revenue Growth | +56.20% | -3.50% | -10.12% | +24.68% | -18.15% | -10.41% | +70.50% | -7.52% | -19.53% | +8.01% | +43.88% | -24.07% | +58.91% | -14.80% | +40.80% | +2.95% | -33.50% | +19.94% | -40.74% | +82.29% | +69.59% | -17.28% | -43.27% | +24.01% | -7.99% | -40.60% | +142.21% | n/a |
| United States Revenue | 216.68M | 193.61M | 191.59M | 180.1M | 168.12M | 157.35M | 142.62M | 135.74M | 129.26M | 118.91M | 117.81M | 111.1M | 100.84M | 90.87M | 101.97M | 90.42M | 87.87M | 72.3M | 73.01M | 65.61M | 61.42M | 64.61M | 59.4M | 54.67M | 49M | 31.25M | 51.69M | 17.93M |
| United States Revenue Growth | +11.92% | +1.05% | +6.38% | +7.13% | +6.84% | +10.33% | +5.07% | +5.01% | +8.70% | +0.93% | +6.05% | +10.17% | +10.97% | -10.89% | +12.77% | +2.91% | +21.53% | -0.97% | +11.27% | +6.82% | -4.94% | +8.79% | +8.63% | +11.59% | +56.82% | -39.56% | +188.27% | n/a |
Operating Expense Breakdown
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 169.85M | 151.27M | 156.64M | 147.01M | 122.33M | 119.08M | 116.79M | 105.11M | 112.56M | 116.57M | 119.31M | 121.49M | 117.28M | 105.7M | 99.87M | 100.28M | 96.09M | 102.27M | 100.79M | 91.39M | 62.2M | 44.9M | 41.15M | 35.24M | 32.88M | 30.47M | 29.66M | 21.59M | 20.57M | 17.83M | 18.35M | 23.9M | 14.6M | 13.51M |
| Selling, General, and Administrative Revenue Growth | +12.28% | -3.43% | +6.55% | +20.17% | +2.73% | +1.96% | +11.12% | -6.62% | -3.44% | -2.30% | -1.79% | +3.59% | +10.96% | +5.83% | -0.41% | +4.36% | -6.04% | +1.47% | +10.29% | +46.93% | +38.53% | +9.12% | +16.75% | +7.19% | +7.91% | +2.72% | +37.36% | +4.96% | +15.37% | -2.83% | -23.23% | +63.67% | +8.10% | n/a |
| Research and Development Revenue | 87.45M | 88.52M | 93.54M | 87.31M | 83.1M | 83.8M | 89.86M | 93.85M | 90.36M | 93.13M | 106.58M | 100.02M | 85.45M | 81.76M | 73.02M | 70.97M | 63.72M | 55.51M | 40.28M | 36.24M | 36.32M | 37.02M | 25.88M | 24.57M | 19.53M | 16.32M | 16.65M | 14.25M | 11.55M | 8.26M | 8.12M | 7.25M | 5.97M | 5.34M |
| Research and Development Revenue Growth | -1.21% | -5.37% | +7.14% | +5.06% | -0.84% | -6.74% | -4.26% | +3.86% | -2.97% | -12.62% | +6.56% | +17.04% | +4.52% | +11.96% | +2.89% | +11.37% | +14.80% | +37.80% | +11.14% | -0.20% | -1.88% | +43.06% | +5.32% | +25.79% | +19.71% | -2.02% | +16.83% | +23.36% | +39.96% | +1.66% | +12.06% | +21.27% | +11.89% | n/a |
| Sales and Marketing Revenue | 119.59M | 104.32M | 104.76M | 97.88M | 81.87M | 80.42M | 79.13M | 68.93M | 71.04M | 76.12M | 81.42M | 80.37M | 73.6M | 64.43M | 59.6M | 50.23M | 47.72M | 34.34M | 31.29M | 25.09M | 25.02M | 25.11M | 22.29M | 18.8M | 19.44M | 17.81M | 17.11M | 13.46M | 11.57M | 11.31M | 9.56M | 7.81M | 7.93M | 7.57M |
| Sales and Marketing Revenue Growth | +14.64% | -0.43% | +7.03% | +19.56% | +1.79% | +1.64% | +14.79% | -2.97% | -6.67% | -6.51% | +1.31% | +9.19% | +14.23% | +8.11% | +18.66% | +5.26% | +38.96% | +9.75% | +24.68% | +0.32% | -0.40% | +12.69% | +18.54% | -3.28% | +9.16% | +4.05% | +27.11% | +16.32% | +2.32% | +18.38% | +22.39% | -1.53% | +4.79% | n/a |